Nascent Biotech Inc., a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma, a clinical and commercial stage drug delivery technology company, have joined forces to develop an alternative delivery mechanism for patients who can benefit from Pritumumab (PTB), Nascent's lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer.
SAN DIEGO, CA / ACCESSWIRE / July 28, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), announced today it has entered into a research collaboration with Syracuse University to further the development of Pritumumab, a unique monoclonal antibody that binds to cell-surface vimentin, for potential use in COVID-19 treatment.
SAN DIEGO, June 24, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTC: NBIO) announced today that it has appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritumumab’s use with viral infections, including COVID-19.
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, and Manhattan BioSolutions, Inc., a biotechnology company focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases, today announced they have entered into a Research Collaboration Agreement to initiate a vaccine program for the potential prevention of COVID-19 or other viral infections. This effort will augment Nascent’s current development plants to investigate the utility of Pritumumab for the treatment of COVID-19 that was announced earlier in March.
SAN DIEGO, April 22, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc., (OTCQB: NBIO) (the “Company” or “Nascent”) a leading biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer, is pleased to present its corporate update and a dynamic strategic plan, which the company has begun executing in 2020.